Randomised phase II screening study to be used in an TPF-chemotherapy [docetaxel + cisplatin + fluorouracil] (short induction) before TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/hypopharynx. [Randomised phase II screeningstudy to be used in a TP/TPF-chemotherapy (shortinduction) before TP/TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/ hypopharynx.]

Trial Profile

Randomised phase II screening study to be used in an TPF-chemotherapy [docetaxel + cisplatin + fluorouracil] (short induction) before TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/hypopharynx. [Randomised phase II screeningstudy to be used in a TP/TPF-chemotherapy (shortinduction) before TP/TPF-induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/ hypopharynx.]

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
  • Indications Laryngeal cancer
  • Focus Therapeutic Use
  • Acronyms DeLOS II
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 25 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by European Clinical Trials Database record.
    • 03 Jun 2014 Primary results (n=126) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top